(Q43882726)

27 November 2017

Thalidomide for the treatment of patients with myelodysplastic syndromes (English)

1 reference

27 November 2017

0 references

Strupp C

1

1 reference

27 November 2017

Germing U

2

1 reference

27 November 2017

Aivado M

3

1 reference

27 November 2017

Misgeld E

4

1 reference

27 November 2017

Haas R

5

1 reference

27 November 2017

Gattermann N

6

1 reference

27 November 2017

language of work or name

1 reference

1 January 2002

1 reference

27 November 2017

1 reference

27 November 2017

16

1 reference

27 November 2017

1-6

1 reference

27 November 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402330

27 November 2017

0 references

cites work

A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402330

7 January 2021

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402330

7 January 2021

The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402330

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402330

7 January 2021

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402330

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402330

7 January 2021

Treatment approaches for relapsing and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402330

7 January 2021

Angiogenesis in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402330

7 January 2021

Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402330

7 January 2021

The occurrence subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: An in vitro study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402330

7 January 2021

Proposals for the classification of the myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402330

7 January 2021

Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402330

7 January 2021

Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402330

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2402330

1 reference

Dimensions Publication ID

27 November 2017

0 references

1 reference